Latest news with #Emcure
Mint
23-05-2025
- Business
- Mint
Shark Tank's Namita Thappar-backed Emcure Pharma shares surge 20% in two sessions after robust Q4 earnings
Shares of Emcure Pharmaceuticals were locked in the 10 per cent upper circuit at ₹ 1,288.65 on Friday, May 23, as the stock extended its rally to the second straight session. The rally comes on the back of a strong performance for the quarter ended March 2025 (Q4FY25). The stock had already surged nearly 9 per cent in the previous session, taking its total two-day gain to about 20 per cent. As of the March 2025 quarter, Shark Tank judge Namita Vikas Thapar owns 50.71 lakh shares or a 2.68 per cent stake of the firm. Emcure reported a 64 per cent year-on-year (YoY) jump in consolidated net profit to ₹ 189 crore in Q4FY25, compared to ₹ 115 crore in the same quarter last year. The revenue from operations rose 20 per cent YoY to ₹ 2,116 crore, up from ₹ 1,771 crore. Sequentially, the company's net profit grew 26.4 per cent, while revenue increased by 7.8 per cent from the previous quarter's net profit of ₹ 156 crore and revenue of ₹ 1,936 crore. According to Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, 'The company delivered a very strong performance in Q4, with all business segments contributing to growth. On the domestic side, we expanded our covered market and built a strong product pipeline. In international markets, we are seeing approvals for our differentiated offerings.' NSE filing by Emcure highlighted strong traction in both domestic and international operations: Domestic business revenue surged 24.8 per cent YoY to ₹ 929 crore, driven by growth in the women's health and cardiology franchises, supported by emerging focus areas like dermatology and OTC products. 929 crore, driven by growth in the women's health and cardiology franchises, supported by emerging focus areas like dermatology and OTC products. International business also expanded, growing 15.6 per cent YoY to ₹ 1,187 crore, led by a 39.3 per cent YoY jump in revenue from the Rest of the World segment to ₹ 481 crore. 1,187 crore, led by a 39.3 per cent YoY jump in revenue from the Rest of the World segment to 481 crore. In Canada, revenue rose 6.2 per cent YoY to ₹ 310 crore, with Mantra—its recent acquisition—now fully integrated. In the European Union, revenue posted a modest 1.7 per cent rise, supported by a recently acquired product portfolio and new regulatory approvals. The company stated that it remains focused on improving margins through new product launches and operating efficiencies, which will be key priorities in FY26. The Board of Directors also recommended a final dividend of ₹ 3 per equity share of face value ₹ 10 each (30 per cent of face value) for the financial year ended March 31, 2025. The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM) and will be paid within the regulatory timelines once approved. Emcure's stock has gained nearly 28 per cent from its IPO price of ₹ 1,008, with the company debuting on the bourses in July 2024. Currently, the pharma stock trades 18 per cent below its record high of ₹ 1,577.50, touched in September 2024. However, it has recovered sharply, rising 45 per cent from its 52-week low of ₹ 890, hit in April 2025. In May 2025 alone, the scrip has jumped over 25 per cent, rebounding from a 5 per cent dip in April. Before that, it gained 9 per cent in March, but had declined 20 percent in February and 15 per cent in January, indicating a recent shift in sentiment.
Mint
23-05-2025
- Business
- Mint
Emcure Pharmaceuticals shares surge 20% in two sessions after robust Q4 earnings
Shares of Emcure Pharmaceuticals were locked in a 10 percent upper circuit at ₹ 1,288.65 on Friday, May 23, as the stock extended its rally for a second straight session. The rally comes on the back of a strong performance for the quarter ended March 2025 (Q4FY25). The stock had already surged nearly 9 percent in the previous session, taking its total two-day gain to about 20 percent. As of the March 2025 quarter, Shark Tank judge Namita Vikas Thapar owns 50.71 lakh share or a 2.68 percent stake of the firm. Emcure reported a 64 percent year-on-year (YoY) jump in consolidated net profit to ₹ 189 crore in Q4FY25, compared to ₹ 115 crore in the same quarter last year. The revenue from operations rose 20 percent YoY to ₹ 2,116 crore, up from ₹ 1,771 crore. Sequentially, the company's net profit grew 26.4 percent, while revenue increased by 7.8 percent from the previous quarter's net profit of ₹ 156 crore and revenue of ₹ 1,936 crore. According to Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, 'The company delivered a very strong performance in Q4, with all business segments contributing to growth. On the domestic side, we expanded our covered market and built a strong product pipeline. In international markets, we are seeing approvals for our differentiated offerings.' NSE filing by Emcure highlighted strong traction in both domestic and international operations: Domestic business revenue surged 24.8 percent YoY to ₹ 929 crore, driven by growth in the women's health and cardiology franchises, supported by emerging focus areas like dermatology and OTC products. International business also expanded, growing 15.6 percent YoY to ₹ 1,187 crore, led by a 39.3 percent YoY jump in revenue from the Rest of the World segment to ₹ 481 crore. In Canada, revenue rose 6.2 percent YoY to ₹ 310 crore, with Mantra—its recent acquisition—now fully integrated. In the European Union, revenue posted a modest 1.7 percent rise, supported by a recently acquired product portfolio and new regulatory approvals. The company stated that it remains focused on improving margins through new product launches and operating efficiencies, which will be key priorities in FY26. The Board of Directors also recommended a final dividend of ₹ 3 per equity share of face value ₹ 10 each (30 percent of face value) for the financial year ended March 31, 2025. The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM), and will be paid within the regulatory timelines once approved. Emcure's stock has gained nearly 28 percent from its IPO price of ₹ 1,008, with the company debuting on the bourses in July 2024. Currently, the pharma stock trades 18 percent below its record high of ₹ 1,577.50, touched in September 2024. However, it has recovered sharply, rising 45 percent from its 52-week low of ₹ 890, hit in April 2025. In May 2025 alone, the scrip has jumped over 25 percent, rebounding from a 5 percent dip in April. Before that, it gained 9 percent in March, but had declined 20 percent in February and 15 percent in January, indicating a recent shift in sentiment. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Canada Standard
22-05-2025
- Business
- Canada Standard
Emcure Pharmaceuticals achieves 63% profit growth, 20% in revenue during Q4-FY25
New Delhi [India], May 22 (ANI): Pune-headquartered pharma company Emcure Pharmaceuticals on Thursday reported that its Profit After Tax or net profit in the January-March 2025 quarter grew 63 per cent to Rs 197 crore. In the same quarter of 2023-24, the pharma company's net profits were at Rs 121 crore. The company's revenue from operations rose 19.5 per cent to Rs 2,116 crore. In the year ago period, the revenue mop up was at Rs 1,771 crore. In the entire year 2024-25, the net profits rose 34.1 per cent to Rs 707 crore, and the revenue from operations rose 18.6 per cent to Rs 7,896 crore. Emcure Pharmaceuticals on Thursday announced its consolidated financial results for the quarter and year ended March 31, 2025. The quarter saw strong performance across both its domestic and international businesses, the pharma company said in a statement. Emcure's domestic business grew by 24.8 per cent, led by its women's health and cardio franchises and further aided by its new focus areas of dermatology and OTC. The international business registered a growth of 15.6 per cent led by a robust 39.3 per cent growth in the Rest of the World segment. Its Canada business continued to perform well with Mantra now fully integrated. In Europe, it recently acquired a portfolio of products and secured key regulatory approvals which will aid growth going forward, it asserted in the statement. Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, 'Emcure delivered a very strong performance in Q4 with all our businesses segments contributing to growth. Over the past year we have effectively executed our strategies across both Domestic and International markets.' 'On the Domestic side we have expanded our covered market and built a strong product pipeline of upcoming launches. In the International markets we are seeing approvals for our differentiated product offerings. Moving forward, while we continue to drive growth, our key priorities will be improving margins through new product launches and operating efficiencies,' Mehta added. Established in 1981, Emcure is currently present in over 70 countries. (ANI)
India Gazette
22-05-2025
- Business
- India Gazette
Emcure Pharmaceuticals achieves 63% profit growth, 20% in revenue during Q4-FY25
New Delhi [India], May 22 (ANI): Pune-headquartered pharma company Emcure Pharmaceuticals on Thursday reported that its Profit After Tax or net profit in the January-March 2025 quarter grew 63 per cent to Rs 197 crore. In the same quarter of 2023-24, the pharma company's net profits were at Rs 121 crore. The company's revenue from operations rose 19.5 per cent to Rs 2,116 crore. In the year ago period, the revenue mop up was at Rs 1,771 crore. In the entire year 2024-25, the net profits rose 34.1 per cent to Rs 707 crore, and the revenue from operations rose 18.6 per cent to Rs 7,896 crore. Emcure Pharmaceuticals on Thursday announced its consolidated financial results for the quarter and year ended March 31, 2025. The quarter saw strong performance across both its domestic and international businesses, the pharma company said in a statement. Emcure's domestic business grew by 24.8 per cent, led by its women's health and cardio franchises and further aided by its new focus areas of dermatology and OTC. The international business registered a growth of 15.6 per cent led by a robust 39.3 per cent growth in the Rest of the World segment. Its Canada business continued to perform well with Mantra now fully integrated. In Europe, it recently acquired a portfolio of products and secured key regulatory approvals which will aid growth going forward, it asserted in the statement. Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, 'Emcure delivered a very strong performance in Q4 with all our businesses segments contributing to growth. Over the past year we have effectively executed our strategies across both Domestic and International markets.' 'On the Domestic side we have expanded our covered market and built a strong product pipeline of upcoming launches. In the International markets we are seeing approvals for our differentiated product offerings. Moving forward, while we continue to drive growth, our key priorities will be improving margins through new product launches and operating efficiencies,' Mehta added. Established in 1981, Emcure is currently present in over 70 countries. (ANI)
Mint
22-05-2025
- Business
- Mint
Emcure Pharmaceuticals to expand gynaecology, derma portfolio for India market in FY26
Pune-headquartered Emcure Pharmaceuticals plans to expand its gynaecology and dermatology product portfolio for the Indian market in FY26, the company's top executive said on Thursday. 'In women's health, we launched a portfolio of products in the menopause and PCOS segment [in FY25],' the company's CEO and managing director Satish Mehta told investors in a post-earnings call. 'We are also in the process of deepening our presence in the gynaecology segment with further launches in FY26,' he added. The firm, which was listed on the stock exchanges in July 2024, reported a profit after tax of ₹ 197 crore in Q4FY25, up 63% year-on-year. Revenue rose 19.5% YoY to ₹ 2,116 crore. The revenue growth was driven by 24.8% growth in its domestic business, and 15.6% growth in its international business, Mehta said. 'In Q4, we had a strong performance from our domestic business, which was led by women's health and cardio and aided by dermatology,' Mehta said. The company's international business, which includes Canada, Europe and rest of the world (RoW) markets, grew 15.6%. 'The key to success is execution and also the focus will be on improving our profitability,' Mehta told investors in the call, referring to the company's FY26 outlook. The company is aiming for a revenue growth of 13-14% in FY26, with about 150 bps margin improvement. Besides launching products in the menopause and PCOS (polycystic ovary syndrome) segment last fiscal year, Emcure sharpened its focus in the dermatology segment with the launch of its subsidiary, Emcutix Biopharmaceuticals. It launched two products focused on cosmetic skincare, a skin-tightening product and a urea-based moisturiser. 'Further pipeline of products will augment our basket of products over the next 12 months,' Mehta said, adding that the company is also seeing a lot of collaboration opportunities for its derma business. Emcure also integrated Sanofi's cardiology portfolio into its business for the Indian market. 'Happy to inform that restructuring of our cardio-diabetic business is complete and we saw a return to normalization during the quarter. We expect this restructuring to drive growth going forward,' said Mehta. Emcure is also in the race for the first-wave of launches of weight-loss drug semaglutide in India next year, and said it is on track for the launch. Going forward, the company will focus on complex injectables, biosimilars and new drug delivery routes for existing molecules, Mehta said. 'The key focus area will be CNS (central nervous system) and derma and we will also be working on ADCs (antibody drug conjugates),' he added.
